Radioimmunoscintigraphy in Patients with Ovarian Cancer

REFERENCES

• Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In DeVita VT, et al., eds. Cancer-principles and practice of oncology, Philadel-phia: Lippincott-Raven, 1997: 1502–1539.
   Google Scholar
• Thigpen JT, Vance RB, Khansur T. Second line chemother-apy for recurrent carcinoma of the ovary. Cancer 1992; 71: 1559–64.
   Google Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med 1993; 329: 1550–9.
   PubMed Web of Science ®Google Scholar
• Howell SB, Kirmani S, McClay EF, Kim S, Braly P, Plaxe S. Intraperitoneal cisplatin-based chemotherapy for ovarian car-cinoma. Semin Oncol 1991; 18 (Suppl 3): 5–10.
   Google Scholar
• Rustin GJS, Gennings JN, Nelstrop AE, Covarrubias H, Lambert HE, Bagshawe KD. Use of Ca-125 to predict sur-vival of patients with ovarian carcinoma. J Clin Oncol 1989; 7: 1667–71.
   PubMedGoogle Scholar
• Goldenberg DM. Perspectives on oncologic imaging with radiolabelled antibodies. Cancer 1997; 80: 2431–5.
   PubMed Web of Science ®Google Scholar
• Epenetos AA, Britton KE, Mather S, et al. Targeting of 123I-labelled tumour associated monoclonal antibodies to ovarian, breast and gastrointestinal tumours. Lancet 1982; ii: 999–1003.
   Google Scholar
• Barzen G, Friedmann W, Richte W, et al. Value of the radio-immunoscintigraphy in the diagnosis and follow-up of ovarian cancer in comparison with computer tomography and second-look surgery. Nuclear Medizin 1992; 31: 16–23.
   Google Scholar
• Surwit EA, Childers JM, Krag DN, et al. Clinical assessment of 1n-CYT-103 immunoscintigraphy in ovarian cancer. Gy-necol Oncol 1993; 48: 285–92.
   PubMed Web of Science ®Google Scholar
• Hempling RE, Piver MS, Baker TR, Baskin S, Gilani SSH. Immunoscintigraphy using 111In-CYT-103 prior to second look laparotomy in ovarian cancer: A pilot study. Am J Clin Oncol 1994; 17: 331–4.
   Google Scholar
• Massuger LFAG, Kenemans P, Claessens RAMJ, et al. Im-munoscintigraphy of ovarian cancer with indium-111-labeled OVTL3 F(ab')2 monoclonal antibody. J Nucl Med 1990; 31: 1802–10.
   PubMed Web of Science ®Google Scholar
• Muto MG, Kassis Al. Monoclonal antibodies used in the detection and treatment of epithelial ovarian cancer. Cancer 1995; 76: 2016–27.
   PubMed Web of Science ®Google Scholar
• Burchell J, Durbin H, Taylor-Papadimitriou J. Complexity of expression of antigenic determinants recognised by monoclonal antibodies HMFG1 and HMFG2 in normal and malignant human mammary epithelial cells. J Immunol 1983; 131: 508–13.
   Google Scholar
• Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinomas. J Clin Invest 1981; 68: 1331–7.
   PubMed Web of Science ®Google Scholar
• Travers P, Bodmer WF. Preparation and characterization of monoclonal antibodies against placental alkaline phosphatase and other human trophoblast associated determinants. Int J Cancer 1984; 33: 633–41.
   Google Scholar
• Durbin H, Tucker DF, Milligan MG, et al. Production of monoclonal antibodies to placental alkaline phosphatase: pre-liminary characterisation includes identification of one antibody reactive with routinely fixed histological preparations. Int J Cancer 1988; (Suppl 2): 50–58.
   Google Scholar
• Fraker PJ, Speck JC. Protein cell membrane iodination with a sparingly soluble chloramine 1,3,4,6-tetrachloro-5,6-diphenyl glycouronil. Biochem Biophys Res Commun 1978; 80: 949–57.
   Google Scholar
• Hnatowich DJ, Childs RL, Lateigne D, Najafi A. The prepa-ration of DTPA-coupled antibodies radiolabeled with metalic radionuclides: an improved method. J Immunol Methods 1983; 65: 147–52.
   PubMed Web of Science ®Google Scholar
• Graham RC, Karnovsky MJ. The early stage of absorption of injected horseradish peroxidase in the proximal tubules of the mouse kidney: ultrastructural histochemistry by a new tech-nique. J Histochem Cytochem 1966; 14: 291–302.
   PubMed Web of Science ®Google Scholar
• Kalofonos HP, Sivolapenko GB, Courtenay-Luck NS, et al. Antibody guided targeting of non-small cell lung cancer using 1111n labeled HMFG1 F(ab')2 fragments. Cancer Res 1988; 48: 1877–84.
   Google Scholar
• Courtenay-Luck NS, Epenetos AA, Moore R, et al. Develop-ment of primary and secondary immune response to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 1986; 46: 6489–93.
   Google Scholar
• Van der Burg MEL, Van Lent M, Buyse M, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995; 332: 629–34.
   Google Scholar
• Kalofonos HP, Kosmas C, Hird V, Snook DE, Epenetos AA. Monoclonal antibodies against placental alkaline phosphatase: immunolocalisation, pharmacokinetics and immune response. Eur J Cancer 1994; 30A: 1842–50.
   Google Scholar
• Kalofonos HP, Pawlikowska TR, Hemingway A, et al. Anti-body guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med 1989; 30: 1636–45.
   PubMed Web of Science ®Google Scholar
• Van Nagell JR, DePriest PD, Gallion HH, Pavlik EV. Ovarian cancer screening. Cancer 1993; 71 (Suppl 4): 1523–1528.
   Google Scholar
• Muto MG, Cramer DW, Brown DL, Welch WR, Harlow BL, Xu H. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol 1993; 51: 12–20.
   PubMed Web of Science ®Google Scholar